In Brief: Selfcare
This article was originally published in The Gray Sheet
Executive Summary
Selfcare: Initial shipments of the firm's electrochemical blood glucose monitoring system to distribution partner Johnson & Johnson's LifeScan subsidiary will be delayed pending an in-house evaluation of the system by J&J, Selfcare announces Sept. 29. Selfcare, which received 510(k) clearance for the system in June, had expected to begin shipments in the third quarter ("The Gray Sheet" July 7, In Brief). Results of the J&J evaluation are due in October. "There can be no assurances that there will not be further delays" in shipments until the results are received, states Selfcare CEO Ron Zwanziger...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.